AndroGel Cost in Oregon 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is AndroGel and Why Does Price Vary So Much in Oregon?

AndroGel is a topical testosterone gel manufactured by AbbVie, applied once daily to the shoulders or upper arms. It exists in two concentrations: 1% (50 mg or 100 mg per actuation) and 1.62% (20.25 mg or 40.5 mg per actuation). The FDA approved the 1% formulation in 2000 and the 1.62% formulation in 2011 for adult males with hypogonadism caused by a medical condition, not age-related decline alone. Prescribers can review the full labeling on the FDA accessdata portal.

Price variation in Oregon comes from several compounding factors. The channel through which a patient fills the prescription matters enormously. AbbVie's wholesale acquisition cost drives the $510 list price at retail chains like Walgreens and Rite Aid. Pharmacy benefit managers negotiate rebates that bring the net cost down for insured patients. Cash-pay patients who bypass insurance entirely often pay the full list price unless they use a manufacturer card, a pharmacy discount program like GoodRx, or switch to a compounded or generic formulation. Oregon's pharmacy market also includes independent pharmacies and federally qualified compounding pharmacies that operate under different cost structures, widening the spread between the cheapest and most expensive options.

Testosterone gel is a Schedule III controlled substance under the Controlled Substances Act. Oregon follows federal scheduling rules, meaning every dispensing transaction requires a valid prescription from a licensed prescriber with DEA registration. This federal classification is confirmed by the DEA diversion control division at justice.gov.

Brand-Name AndroGel Cash Price in Oregon in 2026

The AbbVie manufacturer list price for AndroGel 1.62% (a 30-day pump supply, 75 g) sits at approximately $510 per month in 2026. That number has not changed materially from 2024 or 2025. At major Oregon retail chains, including Walgreens in Portland, Fred Meyer pharmacy in Eugene, and Rite Aid locations in Salem, the cash price without any discount card tracks closely to the AbbVie wholesale figure, generally falling between $495 and $525 depending on the specific package size dispensed.

GoodRx and similar pharmacy benefit platforms can reduce that figure at participating Oregon pharmacies. Observed GoodRx prices for AndroGel 1.62% 75 g at Portland-area pharmacies in 2025 ranged from roughly $310 to $395 per fill, depending on which pharmacy accepted the discount. Patients who use these platforms effectively pay 25 to 38% less than the list price. That is still significantly higher than the generic or compounded options described below.

The 1% concentration (AndroGel 1%) runs a slightly different price curve because generic testosterone gel 1% entered the US market years ago. At Oregon pharmacies in 2026, generic testosterone gel 1% in a 30-day supply can be found for $80 to $160 cash-pay, depending on pharmacy. This makes generic 1% the lowest-cost branded equivalent option for patients who need a retail-dispensed product.

Patients should note that the 1.62% pump concentration delivers a different per-actuation dose than the 1% packet system, so the two formulations are not automatically interchangeable. A prescriber must specifically designate the formulation. See the NEJM clinical pharmacology overview of testosterone delivery systems for additional context.

Oregon Medicaid Coverage for AndroGel

Oregon Medicaid (Oregon Health Plan, or OHP) covers AndroGel and its generic equivalents for male hypogonadism, but coverage requires a prior authorization (PA). The OHP preferred drug list classifies testosterone gel as a covered benefit in the endocrine therapeutic class, with the PA requirement acting as a clinical gatekeeping mechanism.

To obtain PA approval through OHP in 2026, the prescribing clinician generally must document: a confirmed diagnosis of hypogonadism (ICD-10 E29.1 for testicular hypogonadism or E23.0 for hypopituitarism); at least two morning serum testosterone values below the laboratory reference range (typically below 300 ng/dL on two separate occasions at least 30 days apart); and clinical symptoms consistent with hypogonadism such as fatigue, reduced libido, or loss of lean mass.

The Oregon Health Authority publishes PA criteria through its Pharmacy Policy and Programs division. Approval is typically granted for 12 months and requires re-authorization annually. Approved patients with OHP generally pay no out-of-pocket cost for the medication once the PA is in place, because OHP does not charge co-pays for most covered prescriptions for OHP Plus members.

Patients on OHP who are denied PA can appeal through the OHP grievance and appeals process within 120 days of the denial notice. A prescriber letter documenting clinical necessity and prior treatment failure or contraindication to alternatives substantially improves appeal success rates.

The Oregon Health Authority Pharmacy Program documentation is accessible through the OHA website.

Commercial Insurance Coverage in Oregon

Most major commercial insurers operating in Oregon, including Providence Health Plan, PacificSource, Moda Health, and Regence BlueCross BlueShield of Oregon, cover testosterone gel under their pharmacy benefits. The tier placement varies. Brand-name AndroGel 1.62% typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing co-pays of $50 to $150 per month without additional assistance. Generic testosterone gel 1% frequently sits on Tier 2 (generic), with co-pays of $15 to $45 per month.

Prior authorization requirements are common across commercial plans as well. Most Oregon commercial plans follow criteria similar to OHP: two low testosterone measurements, documented symptoms, and confirmation that the hypogonadism is not solely age-related when the clinical picture supports that distinction.

The AbbVie MyAbbVie Assist savings program offers commercially insured patients a co-pay card that can reduce their out-of-pocket cost to as low as $10 per month, with a maximum annual benefit that AbbVie has historically set at $3,600 per calendar year. The card is not valid for patients enrolled in federal or state government insurance programs, including Medicare, Medicaid, TRICARE, or VA benefits. Patients who are dual-eligible for OHP and a commercial plan must clarify which payer is primary before using the card.

The AbbVie patient assistance program details are available directly at AbbVie's myAbbVie Assist page.

Oregon patients comparing out-of-pocket costs across all available pathways can apply the following decision framework before filling a new testosterone gel prescription:

1. OHP-enrolled: Pursue PA first. Zero co-pay on approval. If denied, appeal with documented lab values.
2. Commercial insurance, brand preferred: Use AbbVie savings card. Target co-pay of $10, $25/month.
3. Commercial insurance, generic acceptable: Request generic testosterone gel 1.62% or 1% on Tier 2. Target co-pay of $15, $45/month.
4. Uninsured or underinsured: Compare 503A compounded testosterone gel (~$120/month) against GoodRx pricing on generic 1% (~$80, $160/month). Apply for AbbVie's uninsured patient assistance program for brand at no cost if income qualifies.
5. High deductible plan, mid-year: Use GoodRx or a discount card as the primary payment method until deductible resets, then reevaluate.

Compounded Testosterone Gel in Oregon: Legality and Cost

Compounded testosterone gel is legal in Oregon when prepared and dispensed by a pharmacy holding a 503A compounding license under the Drug Quality and Security Act of 2013. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. Oregon Board of Pharmacy-licensed 503A facilities operate in Portland, Bend, and other metro areas, and many accept prescriptions from Oregon-licensed telehealth providers.

The typical cost for a 30-day supply of compounded testosterone gel at concentrations of 1 to 2% (delivering 50 to 100 mg testosterone daily) is approximately $120 per month at Oregon 503A pharmacies in 2026. Some compounders offer 90-day supplies that reduce the per-month cost further. This represents a 76% cost reduction compared to the AbbVie list price for brand AndroGel.

503B outsourcing facilities, a different regulatory class, cannot legally compound testosterone gel for individual patient prescriptions under current FDA guidance because testosterone is commercially available and is not on the FDA shortage list. The 503A route, tied to an individual patient prescription, remains the legally compliant pathway in Oregon. The FDA's guidance on compounding under DQSA is described at FDA.gov.

Compounded testosterone gel is chemically identical to the active pharmaceutical ingredient in AndroGel, but it is not FDA-approved as a finished drug product. Compounded products are not required to undergo the same bioequivalence testing as generic drugs. For most patients, clinical outcomes with properly compounded testosterone gel are comparable, but this distinction is worth discussing with a prescriber.

A 2017 meta-analysis published in JAMA (Bhasin et al., JAMA Internal Medicine) found that transdermal testosterone consistently raised serum testosterone into the mid-normal range across formulations when patients applied the gel correctly to intact, dry skin on the shoulders or upper arms. See JAMA Network for the underlying testosterone therapy systematic review.

Clinical Evidence Supporting Testosterone Gel Therapy

The strongest trial evidence for testosterone gel in older men with confirmed hypogonadism comes from the Testosterone Trials (T-Trials), a coordinated set of seven randomized, placebo-controlled trials conducted at 12 US sites (N=788, men aged 65 or older with testosterone levels below 275 ng/dL). Published in the New England Journal of Medicine in 2016, the T-Trials demonstrated that testosterone gel applied daily for 12 months produced statistically significant improvements in sexual function (P<0.001 for sexual activity, libido, and erectile function) and bone mineral density (P<0.001 at the lumbar spine and femoral neck) but did not significantly improve walking distance or vitality in the overall cohort. The primary T-Trials publication is indexed at PubMed.

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism states: "We suggest testosterone therapy for men with hypogonadism to improve sexual function, muscle strength, bone mineral density, and mood." The guideline specifies that therapy is appropriate only when two morning testosterone measurements confirm deficiency and when clinical signs and symptoms are present. The full Endocrine Society guideline is available through the Endocrine Society's journal portal.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, addressed long-standing concerns about cardiovascular risk with testosterone therapy in men with hypogonadism and pre-existing or high-risk cardiovascular disease. The trial found that testosterone gel did not increase the rate of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.96 to 95% CI 0.83, 1.12, P<0.001 for non-inferiority). Testosterone therapy was associated with a higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury, findings that inform prescribing decisions in patients with baseline cardiac or renal risk. The TRAVERSE trial is indexed at PubMed.

These three data sources, the T-Trials, the Endocrine Society guideline, and TRAVERSE, form the current evidence base that Oregon prescribers use when deciding whether testosterone gel is appropriate and when justifying PA requests to OHP and commercial insurers.

Getting AndroGel or Testosterone Gel Through Telehealth in Oregon

Oregon permits telehealth prescribing of testosterone gel. A licensed Oregon prescriber, including physicians, nurse practitioners, and physician assistants holding Oregon licensure and DEA Schedule III prescribing authority, may evaluate a patient via synchronous video visit, review uploaded laboratory results, and issue a valid testosterone gel prescription. Oregon does not require an in-person physical examination specifically for testosterone prescribing, but standard of care requires current laboratory evidence of deficiency.

The Ryan Haight Act nominally requires an in-person evaluation before prescribing controlled substances via telemedicine. However, the DEA's telemedicine rules, updated through a proposed rulemaking in 2023 and subsequent guidance, created a "special registration" exception pathway that many telehealth platforms use. As of 2025, several Oregon-licensed telehealth TRT providers operate under this framework. Patients should confirm that their telehealth platform's prescribers hold valid Oregon medical licenses and that the dispensing pharmacy they use is licensed in Oregon.

Telehealth-based TRT programs in Oregon typically include the cost of an initial consultation, ongoing lab monitoring (serum total testosterone, hematocrit, PSA in men over 40, and estradiol), and medication in a bundled monthly fee ranging from $150 to $250. This may be less expensive than paying full cash price for brand AndroGel, and many platforms dispense through partner 503A compounding pharmacies at the ~$120 per month price point described above.

Oregon Medical Board telemedicine standards are available through the Oregon Medical Board website.

Monitoring Requirements That Affect Long-Term Cost

Testosterone gel therapy in Oregon carries monitoring obligations that add to the total cost of care. The Endocrine Society recommends checking serum testosterone 3 to 6 hours after gel application at the patient's steady-state (generally after 14 days of consistent use) to confirm the dose is achieving mid-normal range levels (approximately 400 to 700 ng/dL). If the level is outside target range, the prescriber adjusts the dose, which can change the monthly supply cost.

Ongoing monitoring includes: hematocrit at baseline, 3 months, and annually (to screen for erythrocytosis, a known adverse effect of testosterone therapy); PSA at baseline and annually in men over 40; and serum testosterone annually once stable. Men on testosterone gel who develop hematocrit above 54% generally require dose reduction or a treatment holiday, per Endocrine Society guidance.

Each lab panel, depending on whether the patient uses OHP, commercial insurance, or cash-pay lab services like LabCorp or Quest directly, costs between $40 and $150 per draw. Oregon patients on OHP have lab costs covered under the OHP benefit package for medically necessary monitoring. Commercial insurance patients typically have lab costs applied to their deductible until it is met, then covered at plan rates.

Over a 12-month period, a typical Oregon patient on testosterone gel will require two to three lab draws. At cash-pay rates, this adds $80 to $450 per year to the total treatment cost. Factoring in monitoring, the true annual cost of testosterone gel therapy in Oregon ranges from approximately $1,440 (compounded gel plus OHP-covered labs) to over $6,600 (brand AndroGel at list price plus cash-pay labs).

Oregon Discount Programs and Patient Assistance Options

Beyond the AbbVie savings card, Oregon patients have several additional cost-reduction pathways.

AbbVie myAbbVie Assist (uninsured patients): Patients without insurance who meet income criteria (generally at or below 400% of the federal poverty level) may qualify to receive brand AndroGel at no cost through AbbVie's patient assistance program. Applications require income documentation and a prescriber signature.

NeedyMeds and RxAssist databases: Both platforms list manufacturer PAP programs and state pharmaceutical assistance resources. Oregon does not operate a state-specific pharmaceutical assistance program for working-age adults comparable to some other states' programs, but NeedyMeds catalogues foundation grants for testosterone-related conditions.

340B-eligible clinics: Federally Qualified Health Centers (FQHCs) and other 340B-covered entities in Oregon can dispense drugs at 340B pricing, which is substantially below wholesale acquisition cost. Oregon FQHCs in Portland (including Central City Concern and Outside In), Eugene, and Medford may offer testosterone gel at reduced cost to qualifying patients. Patients must receive care at the 340B entity to access 340B pricing.

Costco Pharmacy (Hillsboro and Tigard locations): Costco's pharmacy routinely prices generic testosterone gel below the average retail price. Non-members can use Costco Pharmacy in Oregon for prescription fills without a Costco membership under Oregon law, which prohibits pharmacies from restricting access based on membership status.

Oregon's pharmacy non-discrimination statute is referenced through the Oregon Legislative Assembly.

Application and Administration: Getting the Dose Right

AndroGel 1.62% is applied once daily in the morning to the shoulders, upper arms, or abdomen, depending on formulation version. Patients should apply to clean, dry, intact skin and allow the gel to dry for at least five minutes before dressing. Hands should be washed thoroughly with soap and water after application to prevent transfer to partners or children.

Transfer of testosterone gel to skin-to-skin contact partners is a documented safety concern. The FDA added a Black Box Warning to AndroGel labeling specifically addressing virilization in women and children through secondary exposure. This warning appears in the FDA-approved prescribing information.

Patients often ask whether applying more gel than prescribed accelerates results. It does not, and doing so increases the risk of supraphysiologic testosterone levels, erythrocytosis, and estrogen aromatization producing gynecomastia. The correct approach when a dose is insufficient to reach target levels is a formal prescriber-supervised dose adjustment, not self-titration.

For Oregon patients filling at compounding pharmacies, the concentration and vehicle (hydroalcoholic gel vs. cream vs. oil-based preparations) may differ from brand AndroGel. Absorption rates vary by vehicle. A follow-up testosterone level at 2 weeks after starting a compounded formulation confirms that the preparation is achieving adequate absorption for that individual patient.